Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review
<b>Background</b>: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers. Giant cells are multinucleated epithelioid cells derived fro...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/1/39 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841549253854363648 |
|---|---|
| author | Muhammad Taqi Haseeb ul Rasool Mobeen Zaka Haider Munjed Al Muderis |
| author_facet | Muhammad Taqi Haseeb ul Rasool Mobeen Zaka Haider Munjed Al Muderis |
| author_sort | Muhammad Taqi |
| collection | DOAJ |
| description | <b>Background</b>: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers. Giant cells are multinucleated epithelioid cells derived from macrophages. Histologically, giant cells are also present in other pathologies of bone, e.g., aneurysmal bone cyst, chondroblastoma, giant cell granuloma, and malignant giant cell tumor, etc. Similarly, radiographic findings overlap with other osteolytic lesions, making the diagnosis and prognosis of giant cell tumor very challenging. <b>Aims and Objectives</b>: The purpose of this study was to explore biological and genetic markers which can be used for detection, differentiation, recurrence, and prognosis of GCTB. This will help to better understand the clinical outcome of GCTB and minimize the need for interventions. <b>Methods</b>: We conducted a literature search using Google, Google Scholar, PubMed, Wiley Library, Medline, Clinical trials.org, and Web of Science. Our search strategy included MeSH terms and key words for giant cell tumor and biogenetic markers from date of inception to September 2020. After excluding review articles, 246 duplicates, and non-relevant articles, we included 24 articles out of 1568 articles, summarizing the role of biogenetic markers in the prognosis of GCT. <b>Results</b>: P63 is 98.6% sensitive and relatively specific for GCT as compared to other multinucleated giant cells containing neoplasms. MDM2 (mouse double minute 2 homolog), IGF1 (insulin-like growth factor 1), STAT1 (signal transducer and activator of transcription 1), and RAC1 (Ras-related C3 botulinum toxin substrate 1) are associated with GCTB recurrence, and might serve as biomarkers for it. Increased expression of the proteins STAT5B, GRB2, and OXSR1 was related to a higher probability of metastasis. H3F3A and H3F3B mutation analysis appears to be a highly specific, although less sensitive, diagnostic tool for the distinction of giant cell tumor of bone (GCTB) and chondroblastoma from other giant cell-containing tumors. A neutrophil to lymphocyte ratio (NLR) > 2.70, platelet to lymphocyte ratio (PLR) > 215.80, lymphocyte to monocyte ratio (LMR) ≤ 2.80, and albumin to globulin ratio (AGR) < 1.50 were significantly associated with decreased disease-free survival (DFS) (<i>p</i> < 0.05). Large amounts of osteoclast-related mRNA (cathepsin K, tartrate-resistant acid phosphatase, and matrix metalloproteinase9) in GCTs (<i>p</i> < 0.05) are associated with the grade of bone resorption. We propose that subarticular primary malignant bone sarcomas with H3.3 mutations represent true malignant GCTB, even in the absence of a benign GCTB component. IMP3 and IGF2 might be potential biomarkers for GCT of the spine in regulating the angiogenesis of giant cell tumor of bone and predicting patients’ prognosis. <b>Conclusions</b>: This review study shows serological markers, genetic factors, cell membrane receptor markers, predictive markers for malignancy, and prognostic protein markers which are highly sensitive for GCT and relatively specific for giant cell tumor. MDM2, IGF1, STAT1, RAC1 are important makers in determining recurrence, while P63 and H3F3A differentiate GCT from other giant cell-containing tumors. STAT5B, GRB2, and OXSR1 are significant in determining the prognosis of GCT. Apart from using radiological and histological parameters, we can add them to tumor work-up for definitive diagnosis and prognosis. |
| format | Article |
| id | doaj-art-25b4695a724e4fdd8a7ef7eaeb730962 |
| institution | Kabale University |
| issn | 2075-4418 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj-art-25b4695a724e4fdd8a7ef7eaeb7309622025-01-10T13:16:32ZengMDPI AGDiagnostics2075-44182024-12-011513910.3390/diagnostics15010039Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative ReviewMuhammad Taqi0Haseeb ul Rasool1Mobeen Zaka Haider2Munjed Al Muderis3Orthopedic Surgery, Macquarie University Hospital, Sydney, NSW 2113, AustraliaInternal Medicine Department, Icahn School of Medicine Mount Sinai, New York, NY 10029, USAInternal Medicine Department, Carle Foundation Hospital, Urbana, IL 61801, USAOrthopedic Surgery, Macquarie University Hospital, Sydney, NSW 2113, Australia<b>Background</b>: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers. Giant cells are multinucleated epithelioid cells derived from macrophages. Histologically, giant cells are also present in other pathologies of bone, e.g., aneurysmal bone cyst, chondroblastoma, giant cell granuloma, and malignant giant cell tumor, etc. Similarly, radiographic findings overlap with other osteolytic lesions, making the diagnosis and prognosis of giant cell tumor very challenging. <b>Aims and Objectives</b>: The purpose of this study was to explore biological and genetic markers which can be used for detection, differentiation, recurrence, and prognosis of GCTB. This will help to better understand the clinical outcome of GCTB and minimize the need for interventions. <b>Methods</b>: We conducted a literature search using Google, Google Scholar, PubMed, Wiley Library, Medline, Clinical trials.org, and Web of Science. Our search strategy included MeSH terms and key words for giant cell tumor and biogenetic markers from date of inception to September 2020. After excluding review articles, 246 duplicates, and non-relevant articles, we included 24 articles out of 1568 articles, summarizing the role of biogenetic markers in the prognosis of GCT. <b>Results</b>: P63 is 98.6% sensitive and relatively specific for GCT as compared to other multinucleated giant cells containing neoplasms. MDM2 (mouse double minute 2 homolog), IGF1 (insulin-like growth factor 1), STAT1 (signal transducer and activator of transcription 1), and RAC1 (Ras-related C3 botulinum toxin substrate 1) are associated with GCTB recurrence, and might serve as biomarkers for it. Increased expression of the proteins STAT5B, GRB2, and OXSR1 was related to a higher probability of metastasis. H3F3A and H3F3B mutation analysis appears to be a highly specific, although less sensitive, diagnostic tool for the distinction of giant cell tumor of bone (GCTB) and chondroblastoma from other giant cell-containing tumors. A neutrophil to lymphocyte ratio (NLR) > 2.70, platelet to lymphocyte ratio (PLR) > 215.80, lymphocyte to monocyte ratio (LMR) ≤ 2.80, and albumin to globulin ratio (AGR) < 1.50 were significantly associated with decreased disease-free survival (DFS) (<i>p</i> < 0.05). Large amounts of osteoclast-related mRNA (cathepsin K, tartrate-resistant acid phosphatase, and matrix metalloproteinase9) in GCTs (<i>p</i> < 0.05) are associated with the grade of bone resorption. We propose that subarticular primary malignant bone sarcomas with H3.3 mutations represent true malignant GCTB, even in the absence of a benign GCTB component. IMP3 and IGF2 might be potential biomarkers for GCT of the spine in regulating the angiogenesis of giant cell tumor of bone and predicting patients’ prognosis. <b>Conclusions</b>: This review study shows serological markers, genetic factors, cell membrane receptor markers, predictive markers for malignancy, and prognostic protein markers which are highly sensitive for GCT and relatively specific for giant cell tumor. MDM2, IGF1, STAT1, RAC1 are important makers in determining recurrence, while P63 and H3F3A differentiate GCT from other giant cell-containing tumors. STAT5B, GRB2, and OXSR1 are significant in determining the prognosis of GCT. Apart from using radiological and histological parameters, we can add them to tumor work-up for definitive diagnosis and prognosis.https://www.mdpi.com/2075-4418/15/1/39biogenetic markers of GCTgiant cell tumorprognostic markers for GCT |
| spellingShingle | Muhammad Taqi Haseeb ul Rasool Mobeen Zaka Haider Munjed Al Muderis Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review Diagnostics biogenetic markers of GCT giant cell tumor prognostic markers for GCT |
| title | Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review |
| title_full | Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review |
| title_fullStr | Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review |
| title_full_unstemmed | Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review |
| title_short | Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review |
| title_sort | significance of biogenetic markers in giant cell tumor differentiation and prognosis a narrative review |
| topic | biogenetic markers of GCT giant cell tumor prognostic markers for GCT |
| url | https://www.mdpi.com/2075-4418/15/1/39 |
| work_keys_str_mv | AT muhammadtaqi significanceofbiogeneticmarkersingiantcelltumordifferentiationandprognosisanarrativereview AT haseebulrasool significanceofbiogeneticmarkersingiantcelltumordifferentiationandprognosisanarrativereview AT mobeenzakahaider significanceofbiogeneticmarkersingiantcelltumordifferentiationandprognosisanarrativereview AT munjedalmuderis significanceofbiogeneticmarkersingiantcelltumordifferentiationandprognosisanarrativereview |